Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone

BD Cheson; PC Trask; JG Gribben; N Dimier; E Kimby; Elly Lugtenburg; C Thieblemont; E Wassner-Fritsch; A Launonen; L H Sehn

doi:10.1007/s00277-016-2878-5

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone

BD Cheson, PC Trask, JG Gribben, N Dimier, E Kimby, Elly Lugtenburg, C Thieblemont, E Wassner-Fritsch, A Launonen, L H Sehn

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

5 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	253-259
Number of pages	7
Journal	Annals of Hematology
Volume	96
Issue number	2
DOIs	https://doi.org/10.1007/s00277-016-2878-5
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.1007/s00277-016-2878-5

REPUB_108445_OA.pdfFinal published version, 508 KB

http://hdl.handle.net/1765/108445

Cite this

Cheson, BD., Trask, PC., Gribben, JG., Dimier, N., Kimby, E., Lugtenburg, E., Thieblemont, C., Wassner-Fritsch, E., Launonen, A., & Sehn, L. H. (2017). Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Annals of Hematology, 96(2), 253-259. https://doi.org/10.1007/s00277-016-2878-5

@article{6b49651040d443c4a54be07b87218f07,

title = "Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone",

author = "BD Cheson and PC Trask and JG Gribben and N Dimier and E Kimby and Elly Lugtenburg and C Thieblemont and E Wassner-Fritsch and A Launonen and Sehn, {L H}",

year = "2017",

doi = "10.1007/s00277-016-2878-5",

language = "Undefined/Unknown",

volume = "96",

pages = "253--259",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science+Business Media",

number = "2",

}

Cheson, BD, Trask, PC, Gribben, JG, Dimier, N, Kimby, E, Lugtenburg, E, Thieblemont, C, Wassner-Fritsch, E, Launonen, A & Sehn, LH 2017, 'Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone', Annals of Hematology, vol. 96, no. 2, pp. 253-259. https://doi.org/10.1007/s00277-016-2878-5

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone

AU - Cheson, BD

AU - Trask, PC

AU - Gribben, JG

AU - Dimier, N

AU - Kimby, E

AU - Lugtenburg, Elly

AU - Thieblemont, C

AU - Wassner-Fritsch, E

AU - Launonen, A

AU - Sehn, L H

PY - 2017

Y1 - 2017

U2 - 10.1007/s00277-016-2878-5

DO - 10.1007/s00277-016-2878-5

M3 - Article

C2 - 27900446

SN - 0939-5555

VL - 96

SP - 253

EP - 259

JO - Annals of Hematology

JF - Annals of Hematology

IS - 2

ER -